Omeros reported $0 in Sales Revenues for its fiscal quarter ending in March of 2022.





Sales Change Date
Adma Biologics USD 124.4M 9.9M Jun/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Cytokinetics USD 47.6M 19M Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Insmed USD 524.42M 98.93M Sep/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
MacroGenics USD 32.83M 12.03M Jun/2026
Pacira USD 176.65M 15.75M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Rockwell Medical USD 25.83M 3.15M Jun/2024
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
United Therapeutics USD 832.5M 49.2M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026